瘤微环境驱动的免疫逃避和治疗策略在头部和部状细胞癌中
Ingeborg Tinhofer1, Anne-Sophie Fisch
1Department of Radiooncology and Radiotherapy, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Current opinion in oncology
|March 6, 2026
概括
头部和部状细胞癌 (HNSCC) 瘤微环境 (TME) 抵抗免疫检查点抑制剂 (ICI). 用新的组合准TME障碍物显示出改善HNSCC患者持久反应的希望.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
背景情况:
- 头部和部状细胞癌 (HNSCC) 呈现出复杂的瘤微环境 (TME),促进免疫逃避.
- 免疫检查点抑制剂 (ICI) 在HNSCC中具有有限的持久响应率,这是由于体内壁垒,髓状细胞透和TME内的代谢约束.
研究的目的:
- 审查HNSCC TME中的免疫抵抗机制.
- 突出针对TME的新兴治疗策略,以提高ICI的疗效.
主要方法:
- 使用多重免疫组织化学/免疫光 (IHC/mIF).
- 采用单细胞和空间欧米克技术.
- 进行计算型TME分析.
主要成果:
- 确定了包括CAF驱动的免疫排斥,通过化学因子和缺氧招募髓状细胞以及影响效应T细胞的营养物质/氧气竞争等抵抗机制.
- 突出的TME向组合与PD-(L) 1阻断,如VEGFR/多酶抑制剂,TGF-β/CAF导向剂,骨髓蛋白/化学因子调节剂和代谢干预措施.
结论:
- HNSCC TME既是一个重要的障碍,也是一个治疗目标.
- 将高分辨率的TME分析整合到临床试验中,对于选择最佳的TME匹配组合和识别可能从免疫治疗中受益的患者子集至关重要.
相关概念视频
The Tumor Microenvironment
8.0K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
8.0K
Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Cancer Therapies
10.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.5K
Adaptive Mechanisms in Cancer Cells
7.2K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Cytotoxic T Cells-mediated Immune Response
7.7K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.7K


